https://scholars.lib.ntu.edu.tw/handle/123456789/537419
標題: | Higher decorin levels in bone marrow plasma are associated with superior treatment response to novel agent-based induction in patients with newly diagnosed myeloma - A retrospective study | 作者: | SHANG-YI HUANG Lin H.-H. MING YAO JIH-LUH TANG SHANG-JU WU HSIN-AN HOU WEN-CHIEN CHOU SHENG-CHIEH CHOU SZU-CHUN HSU BOR-SHENG KO Lu H.-Y. WOEI TSAY HWEI-FANG TIEN |
公開日期: | 2015 | 出版社: | Public Library of Science | 卷: | 10 | 期: | 9 | 來源出版物: | PLoS ONE | 摘要: | The growth of myeloma cells depends on bone marrow (BM) stroma consisting of stromal cells, secreted cytokines and the extracellular matrix (ECM). Decorin, a small leucine-rich proteoglycan in the ECM, is a signaling ligand and native anti-tumor agent. However, the role of decorin in patients with myeloma is not clear. We evaluated the correlation between the decorin levels measured by enzyme-linked immunosorbent assay in BM plasma from 121 patients with newly diagnosed myeloma based on their clinical features and treatment response. The median decorin levels in the patients and the normal control group were 12.31 ng/mL [standard deviation (SD), 7.50 ng/mL; range, 2.45 to 44.46 ng/mL] and 10.31 ng/mL (SD, 2.42 ng/mL; range, 4.85-15.14 ng/mL), respectively (P < 0.001). Using 15.15 ng/mL as a cut-off, 46 patients (38%) exhibited higher decorin levels (H-DCN), whereas the other patients exhibited normal to lower decorin levels (NL-DCN). Except for the median age, which was significantly younger in the H-DCN than in the NL-DCN group (60.6±14.0 vs. 65.8±12.2 years, respectively; P = 0.034), there were no differences between the two groups. However, in 79 patients who had received novel agent-based induction, the overall response rate was significantly better in the H-DCN than in the NL-DCN (97 vs. 63%, respectively; P < 0.001), as was the depth of responses (P = 0.008), which were not observed in those who had received chemotherapeutic agents alone. Progression-free survival (PFS) was significantly longer in H-DCN than NL-DCN (not reached vs. 19.5 mo, respectively; P = 0.0003). Multivariate analyses indicated that H-DCN, as a significantly independent factor, was associated with better treatment response (odds ratio, 20.014; 95% CI, 2.187-183.150; P = 0.008) and longer PFS (hazard ratio, 0.135; 95% CI, 0.051- 0.361; P < 0.001). These findings disclose the potential role of decorin in myeloma and provide a basis for further study on possible synergistic anti-myeloma effects between decorin and the novel agents that target BM stroma. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84945547288&doi=10.1371%2fjournal.pone.0137552&partnerID=40&md5=e4104d4a0b0ecf214e81ef3308bcf1e1 https://scholars.lib.ntu.edu.tw/handle/123456789/537419 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0137552 | SDG/關鍵字: | bortezomib; cyclophosphamide; decorin; dexamethasone; doxorubicin; melphalan; prednisolone; thalidomide; vincristine; antineoplastic agent; cytokine; DCN protein, human; decorin; adult; aged; Article; bone marrow; clinical feature; continuous infusion; controlled study; drug megadose; enzyme linked immunosorbent assay; female; human; major clinical study; male; multiple myeloma; overall survival; progression free survival; protein blood level; retrospective study; treatment response; bone marrow cell; cell proliferation; disease free survival; extracellular matrix; induction chemotherapy; metabolism; middle aged; mortality; multiple myeloma; pathology; procedures; secretion (process); treatment outcome; young adult; Adult; Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Proliferation; Cytokines; Decorin; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Extracellular Matrix; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。